Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment

Virology. 2025 Jan:602:110318. doi: 10.1016/j.virol.2024.110318. Epub 2024 Nov 26.

Abstract

Timely initiation of antiretroviral therapy (ART) remains a major challenge in the effort to treat children living with HIV ("CLH") and little is known regarding the dynamics of immune normalization following ART in CLH with varying times to and durations of ART. Here, we leveraged two cohorts of virally-suppressed CLH from Nairobi, Kenya to examine differences in the peripheral immune systems between two cohorts of age-matched children (to control for immune changes with age): one group which initiated ART during early HIV infection and had been on ART for 5-6 years at evaluation (early, long-term treated; "ELT" cohort), and one group which initiated ART later and had been on ART for approximately 9 months at evaluation (delayed, short-term treated; "DST" cohort). We profiled PBMC and purified NK cells from these two cohorts by mass cytometry time-of-flight (CyTOF). Although both groups of CLH had undetectable viral RNA load at evaluation, there were marked differences in both immune composition and immune phenotype between the ELT cohort and the DST cohort. DST donors had reduced CD4 T cell percentages, decreased naive to effector memory T cell ratios, and markedly higher expression of stress-induced markers. Conversely, ELT donors had higher naive to effector memory T cell ratios, low expression of stress-induced markers, and increased expression of markers associated with an effective antiviral response and resolution of inflammation. Collectively, our results demonstrate key differences in the immune systems of virally-suppressed CLH with different ages at ART initiation and durations of treatment and provide further rationale for emphasizing early onset of ART.

Keywords: ART; HIV; Immunology; Monocytes; NK cells; Pediatric HIV; T cells.

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / immunology
  • HIV Infections* / virology
  • HIV-1 / drug effects
  • HIV-1 / immunology
  • Humans
  • Kenya
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology
  • Leukocytes, Mononuclear / immunology
  • Male
  • Time Factors
  • Viral Load*

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents